JOSE MARIA SOARES JUNIOR
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina - Docente
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
- Interpretations on a rare localization of endometriosis: labium minus(2021) SENGUL, Ilker; SENGUL, Demet; SOARES JUNIOR, Jose Maria
- Caesarean section scar endometriosis: quo vadis?(2022) SENGUL, Demet; SENGUL, Ilker; SOARES JUNIOR, Jose Maria
- Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy(2023) GUTIC, Bojana; BOZANOVIC, Tatjana; MANDIC, Aljosa; DUGALIC, Stefan; TODOROVIC, Jovana; STANISAVLJEVIC, Dejana; DUGALIC, Miroslava Gojnic; SENGUL, Demet; DETANAC, Dzenana A.; SENGUL, Ilker; DETANAC, Dzemail; SOARES JUNIOR, Jose MariaProgrammed Cell Death-1 (PCD-1) is a key immune checkpoint receptor, which mainly expresses on activated T, B, Dendritic (DC), Natural Killer (NK), and Treg cells. On the surface of activated T-cells, PCD-1 expression is upregulated after the recognition of peripherals antigens by T cells; subsequently, the elevated binding of PD-1 to Programmed Death Ligand-1 (PD-L1) and Programmed Death Ligand-2 (PD-L2) becomes a key step for downstream inhibitory signaling. Although the role of PD-L1 has been evaluated more thoroughly by clinical research, and PD-L1 has also been used more widely in the clinical setting, PD-L2 also plays an important role in the negative regulation of T-cells, one of the necessary conditions that lead to immune tolerance. Expression of PD-L1 either in tumors or in infiltrating immune cells has been verified predominantly by Immunohistochemistry (IHC) in a variety of tumors, suggesting a role for the PD-1/PD-L1 axis as a prognostic trait and therapeutic target across multiple histotypes. The complex interplay between these factors plays a major role in the diffusion and clinical application of PD-L1 IHC assays as predictive biomarkers of response to PD-1/PD-L1 inhibitors. Checkpoint blockades are registered for the treatment of various cancers, including gynecological malignancies.
- Evaluation of breast stiffness pathology based on breast compression during mammography: Proposal for novel breast stiffness scale classification(2022) PROKOP, Jiri; MARSALEK, Pavel; SENGUL, Ilker; PELIKAN, Anton; JANOUTOVA, Jana; HORYL, Petr; ROMAN, Jan; SENGUL, Demet; SOARES JUNIOR, Jose MariaBreast cancer is diagnosed through a patient's Breast Self-Examination (BSE), Clinical Breast Examination (CBE), or para-clinical methods. False negativity of PCM in breast cancer diagnostics leads to a persisting problem associ-ated with breast tumors diagnosed only in advanced stages. As the tumor volume/size at which it becomes inva-sive is not clear, BSE and CBE play an exceedingly important role in the early diagnosis of breast cancer. The quality and effectiveness of BSE and CBE depend on several factors, among which breast stiffness is the most important one. In this study, the authors present four methods for evaluating breast stiffness pathology during mammography examination based on the outputs obtained during the breast compression process, id est, without exposing the patient to X-Ray radiation. Based on the subjective assessment of breast stiffness by experienced medical examiners, a novel breast stiffness classification was designed, and the best method of its objective mea-surement was calibrated to fit the scale. Hence, this study provides an objective tool for the identification of patients who, being unable to perform valid BSE, could benefit from an increased frequency of mammography screening. Dum vivimus servimus.